Magnolia Market Access at ISPOR 2025
Advancing Evidence. Expanding Access.
May 13-16, 2025 | Palais des congrès de Montréal
Magnolia Market Access is heading to ISPOR 2025 in Montréal to share new research and connect with leaders across HEOR, market access, and real-world evidence. Our team will present two new posters focused on frailty, risk stratification, and outcomes modeling—shedding light on how aging and high-risk populations impact value frameworks and access decisions. Our team will also present a poster featuring insights from our IRA Payer Insights Survey, which explores how payers are adapting their strategies in response to the initial list of 10 drugs selected for Medicare Drug Price Negotiation.
We’re looking forward to high-impact conversations throughout the week. If you’re navigating complex payer landscapes or evolving evidence requirements, let’s meet.
Featured Research at ISPOR 2025
Our work this year focuses on bridging real-world data complexity with actionable insights for manufacturers and payers. From frailty assessment to modeling implications, our posters tackle timely questions with strategic relevance.
Poster Highlights
View our posters and meet with the authors in the Exhibit Hall.
Frailty Indices Using Claim Data – Examples from a Hospitalized Medicare Population
Poster Session 1: May 14 | 10:30 AM – 1:30 PM
Poster: MSR14
Authors: Mike Murphy, Jessica Duchen, Pamela Landsman-Blumberg
Discordance Between Two Claims-Based Frailty Indices in a Hospitalized Medicare Population
Poster Session 1: May 14 | 10:30 AM – 1:30 PM
Poster: MSR20
Authors: Mike Murphy, Jessica Duchen, Pamela Landsman-Blumberg
Payer Survey Uncovers Likely Increased Management Strategies Following Release of Initial 10 Drugs Selected for Price Negotiation
Poster Session 5: May 16 | 9:00 AM – 11:30 AM
Poster: MPR148
Authors: Rachel Besse, Parker Edman, Jessica Duchen, Amanda Forys
Featured Q&A: Frailty and the Access Imperative
In a special pre-event interview: Mike Murphy, Director of Real-World Evidence, shares how frailty measurement is reshaping real-world data strategy—and why biopharma can’t afford to ignore it.
“Treatments that are standard of care in non-frail patients might not be appropriate—or safe—for those who are frail. If we want to close those gaps with real-world evidence, we have to measure frailty accurately and consistently.”
– Mike Murphy
Request a Meeting with Our Team
We’d love to connect during ISPOR to discuss real-world data strategy in high-risk populations, evidence planning for aging-related access questions, and how value-based frameworks are shaping payer expectations. Whether you’re building a new HEOR plan or refining your current model, let’s start a conversation.
"*" indicates required fields
Meet the Team:
Mike Murphy
Director, Real World Evidence and HEOR Strategy
Jessica Duchen
VP, Real-World Evidence & HEOR Strategy